Insulin Receptor – Drugs In Development, 2024

Powered by

Unlock hidden opportunities in the Pharmaceuticals industry


The Insulin Receptor pipeline drugs market research report outlays comprehensive information on the Insulin Receptor targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers products from therapy areas such as Metabolic Disorders, Oncology, Ophthalmology, and Central Nervous System which include indications of Type 2 Diabetes, Type 1 Diabetes (Juvenile Diabetes), Non-Small Cell Lung Cancer, Hepatocellular Carcinoma, Graves’ Ophthalmopathy, Retinopathy Of Prematurity, Alzheimer’s Disease, and Parkinson’s Disease. It also reviews key players involved in Insulin Receptor targeted therapeutics development with respective active and dormant or discontinued projects.


* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.

* Certain sections in the report may be removed or altered based on the availability and relevance of data.

Quick View – Insulin Receptor
Therapy Area
· Cardiovascular; Central Nervous System; Gastrointestinal; Genetic Disorders; Genito Urinary System; Hormonal Disorders; Immunology; Metabolic Disorders; Musculoskeletal Disorders; Oncology; Ophthalmology; Respiratory; Undisclosed
Key Mechanisms of Action
· Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC Agonist; Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC Antagonist; Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC Inhibitor; Insulin Receptor (IR or CD220 or INSR or EC Agonist; Insulin Receptor (IR or CD220 or INSR or EC Antagonist; Insulin Receptor (IR or CD220 or INSR or EC Inhibitor
Key Routes of Administration
· Subcutaneous; Oral; Parenteral; Intravenous; Inhalational; Nasal; Transdermal; Sublingual; Ophthalmic; and Buccal
Key Companies
· Sihuan Pharmaceutical Holdings Group Ltd; Tonghua Dongbao Pharmaceutical Co Ltd; Biogenomics Ltd; Novo Nordisk AS; GeneSys Biologics Pvt Ltd; Geropharm; Thermalin Inc; The United Laboratories International Holdings Ltd; Gan & Lee Pharmaceuticals Co Ltd; and Adocia SAS
Key Molecule Type
· Recombinant Protein; Small Molecule; Fusion Protein; Monoclonal Antibody; Synthetic Peptide; Recombinant Peptide; Subunit Vaccine; Peptide; Gene Therapy; and Antisense Oligonucleotide


  • The report provides a snapshot of the global therapeutic landscape for Insulin Receptor
  • The report reviews Insulin Receptor targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Insulin Receptor targeted therapeutics and enlists all their major and minor projects
  • The report assesses Insulin Receptor targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Insulin Receptor targeted therapeutics

Reasons to Buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Insulin Receptor Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Insulin Receptor development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Key Players

9 Meters Biopharma Inc; Abvance Therapeutics Inc; Acelyrin Inc; Adocia SAS; Aerami Therapeutics Inc; Akston Biosciences Corp; America Great Health; AmideBio
LLC; Aphios Corp; Aptamer Sciences Inc; Arecor Therapeutics Plc; Axelar AB; Biocon Ltd; Biogenomics Ltd; BioLingus AG; Biozeus Pharmaceutical SA; Cavalry Biosciences Inc; Celerity Pharmaceuticals LLC; Centaurus Biopharma Co Ltd; Chinese People's Liberation Army; Chongqing Chenan BioPharm Co Ltd; Cour Pharmaceuticals Development Co Inc; Daewoong Pharmaceutical Co Ltd; Diabetology (Products) Ltd; Diasome Pharmaceuticals Inc; EastGate Pharmaceuticals Inc; Elgan Pharma Ltd; Eli Lilly and Co; Emory University; Epichem Pty Ltd; Ewha Womans University; Gan & Lee Pharmaceuticals Co Ltd; Genervon Biopharmaceuticals LLC; GeneSys Biologics Pvt Ltd; Genova Biotech Company Ltd; Geropharm; GRO Biosciences Inc; Gubra ApS; Hangzhou Tianlong Pharmaceutical Co Ltd; Hanmi Pharmaceuticals Co Ltd; HEC Pharma Co Ltd; Horizon Therapeutics Plc; Hua Medicine Shanghai Ltd; Huadong Medicine Co Ltd; ImmunoForge Co Ltd; ImmunoGen Inc; Immunwork Inc; Imugene Ltd; Innopharmax Inc; Innovent Biologics Inc; Jiangsu Hengrui Medicine Co Ltd; Karyo Biologics LLC; Lannett Co Inc; LATITUDE Pharmaceuticals Inc; MannKind Corp; Martin Luther University Halle-Wittenberg; McGill University; Medlab Clinical Ltd; Merck & Co Inc; Millennium Pharmaceuticals Inc; Minghui Pharmaceutical (Shanghai) Co Ltd; Nanjing Hanxin Pharmaceutical Technology Co Ltd; Nico Innovagroup Srl; NightHawk Biosciences Inc; Ningbo Kunpeng Biotech Co Ltd; Novo Nordisk AS; Oak Hill Bio Inc; OPKO Health Inc; Oramed Pharmaceuticals Inc; Paras Biopharmaceuticals Finland Oy; Polus Inc; Precigen Inc; Prometheon Pharma LLC; Protomer Technologies Inc; Purzer Pharmaceutical Co Ltd; Rani Therapeutics LLC; Rezolute Inc; Sanofi; Sekkei Inc; Sensulin LLC; Seoul National University; Seurat Therapeutics Inc; Shenyang Research Institute of Chemical Industry Co Ltd; SIFI SpA; Sihuan Pharmaceutical Holdings Group Ltd; Silver Creek Pharmaceuticals Inc; Sino Biopharmaceutical Ltd; Sling Therapeutics Inc; Stelis Biopharma Ltd; Sunshine Lake Pharma Co Ltd; Surf Bio Inc; Suzhou Pro-Heal Pharmaceutical Technology Co Ltd; The Florey Institute of Neuroscience and Mental Health; The United Laboratories International Holdings Ltd; The Walter and Eliza Hall Institute of Medical Research; Thermalin Inc; Thomas Jefferson University; Tonghua Dongbao Pharmaceutical Co Ltd; Transdermal Delivery Solutions Corp; Transgene Biotek Ltd; University of Auckland; University of Houston; University of Nebraska; University of North Carolina at Chapel Hill; University of Rochester; University of Washington; Valin Technologies Ltd; Viridian Therapeutics Inc; Wanbang Biopharmaceuticals Co Ltd; Wockhardt Ltd; Xeris Biopharma Holdings Inc; XL-protein GmbH; XOMA Corp; Zenas BioPharma (USA) LLC; Zhejiang Hisun Pharmaceutical Co Ltd; Zhuhai Gene-Biocon Biological Technology Co Ltd; Zhuhai United Laboratories Co Ltd

Table of Contents

Table of Contents

List of Tables

List of Figures


Global Markets Direct Report Coverage


Therapeutics Development

Drugs under Development by Stage of Development

Drugs under Development by Therapy Area

Drugs under Development by Indication

Drugs under Development by Companies

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Companies Involved in Therapeutic Development

Drug Profiles

Dormant Projects

Discontinued Drugs

Product Development Milestones




Secondary Research

Primary Research

Expert Panel Validation

Contact Us



List of Tables

Number of Drugs under Development by Stage of Development, 2024

Number of Drugs under Development by Therapy Areas, 2024

Number of Drugs under Development by Indication, 2024

Number of Drugs under Development by Companies, 2024

Drugs under Development by Companies, 2024

Number of Drugs by Stage and Mechanism of Actions, 2024

Number of Drugs by Stage and Route of Administration, 2024

Number of Drugs by Stage and Molecule Type, 2024

Dormant Drugs, 2024

Discontinued Drugs, 2024


List of Figures

Number of Drugs under Development by Stage of Development, 2024

Number of Drugs under Development by Therapy Areas, 2024

Number of Drugs under Development by Indications, 2024

Number of Drugs by Stage and Mechanism of Actions, 2024

Number of Drugs by Routes of Administration, 2024

Number of Drugs by Stage and Routes of Administration, 2024

Number of Drugs by Molecule Types, 2024

Number of Drugs by Stage and Molecule Types, 2024

Frequently asked questions

Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
5-Hydroxytryptamine Receptor 2A - Drugs In Development, 2024
$3,500 | June 2024
Mu Type Opioid Receptor - Drugs In Development, 2024
$3,500 | June 2024
GTPase KRas - Drugs In Development, 2024
$3,500 | June 2024
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Insulin Receptor – Drugs In Development, 2024 in real time.

  • Access a live Insulin Receptor – Drugs In Development, 2024 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.